Leading Product Sales

Estimated sales for 2022 is disclosed in International Financial Reporting Standards (IFRS).

May 11. 2022

(¥ million)

Brand name Active Ingredient Indications Launch Date Sales 2020
(JGAAP)
Sales 2021
(JGAAP)
Sales 2022 (IFRS)
(estimated)
Apr-Sep Annual
Vidaza azacitidine myelodysplastic syndrome/
acute myeloid leukemia
Mar-2011/
Mar-2021
15,350 18,338 7,800 12,400
Uptravi selexipag pulmonary arterial hypertension/
chronic thromboembolic pulmonary hypertension
Nov-2016/
Aug-2021
6,804 8,400 4,500 9,800
Viltepso       2,387 7,750 5,900 13,000
(Japan) viltolarsen Duchenne muscular
dystrophy
Japan May-2020
U.S. Aug-2020
(1,953) (4,059) (2,200) (4,750)
(U.S.)       (434) (3,691) (3,700) (8,250)
Tramal, Onetram tramadol hydrochloride cancer pain, chronic pain Sep-2010 6,906 6,770 2,700 5,000
Gazyva obinutuzumab CD20-positive follicular lymphoma Aug-2018 5,312 5,300 2,700 5,800
Adcirca tadalafil pulmonary arterial hypertension Dec-2009 5,474 4,563 1,400 2,500
Zalutia tadalafil urinary disorder caused by benign prostatic hyperplasia Apr-2014 6,743 4,106 1,300 2,300
Cialis tadalafil erectile dysfunction Jul-2009 2,677 2,532 1,250 2,600
Erizas dexamethasone cipecilate allergic rhinitis Dec-2009 2,444 2,330 700 2,400
Defitelio defibrotide sodium sinusoidal obstruction syndrome Sep-2019 1,970 2,128 1,000 2,300
Profit in co-promotion   8,442 8,934 4,600 9,500
Revenues from the licensing of industrial property rights   24,338 33,207 14,600 29,800
Pharmaceuticals   106,478 120,650 57,400 115,000
Functional Food   15,406 16,897 9,600 19,000
Net Sales   121,885 137,547 67,000 134,000